We are really pleased with the excellent results achieved inside our Phase 2/3 EASED trial.

Related StoriesResearchers perform focused ultrasound remedies in the U first.S. For dyskinesiaDiabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of PolyphotonixArticle explores viewpoints on role of gentle cognitive impairment in Parkinson's disease Treatment with ADS-5102 did not result in worsening of PD, as measured by the MDS-UPDRS combined score . Data from the Phase 2/3 study were offered today in a poster entitled ‘Protection and Efficacy of ADS-5102 in Levodopa-Induced Dyskinesia ‘ in 11:30 am ET at the World Parkinson's Congress in Montreal, Canada.. Adamas Pharmaceuticals reports excellent results from ADS-5102 Stage 2/3 EASED clinical trial Adamas Pharmaceuticals, Inc. ‘We are really pleased with the excellent results achieved inside our Phase 2/3 EASED trial, and the magnitude of the transformation in ON time without troublesome dyskinesia in Parkinson's patients experiencing LID.Methods Study Participants The protocol of the Pancreatitis, Very Early Weighed against Selective Delayed Begin of Enteral Feeding trial has been published previously33 and is available with the full text of this article at NEJM.org. The study was conducted based on the protocol. Adults with an initial episode of severe pancreatitis who had been at high risk for complications were permitted undergo randomization. Sufferers were regarded as at high risk for complications if, within a day after display to the emergency section, the Severe Physiology and Chronic Wellness Evaluation II34 score was 8 or more , if the Imrie or modified Glasgow rating35 was 3 or more , or if the serum C-reactive protein level was more than 150 mg per liter.36 These assessments predict the development of complications during the condition.